Skip to main content
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
letter
. 2005 May;58(5):559.

A case of Aspergillus fumigatus peritonitis in a patient undergoing continuous ambulatory peritoneal dialysis (CAPD): diagnostic and therapeutic challenges

L Ide 1, E De Laere 1, A Verlinde 1, I Surmont 1
PMCID: PMC1770664  PMID: 15858136

In the June 2004 issue of your journal, Scotter described a case of aspergillus peritonitis in a patient undergoing renal dialysis diagnosed by the polymerase chain reaction and galactomannan detection.1

We had a similar case of aspergillus peritonitis detected by (repeated) culture of peritoneal fluid and a positive serum galactomannan detection test.

An 82 year old man under continuous ambulatory peritoneal dialysis was referred to our hospital because of chronic dyspnoea, persistent cough with production of white sputum, fever, and abdominal pain. He was known to have diabetes mellitus and corticodependent chronic obstructive pulmonary disease. He developed a documented polymicrobial bacterial peritonitis, which was adequately treated. A few days later Aspergillus fumigatus was repeatedly cultured from his sputum. A bronchial aspirate also yielded A fumigatus. Because of persistent abdominal pain, peritoneal fluid was cultured using BacT/ALERT® FA aerobic and SN anaerobic culture bottles (bioMérieux, Marcy-L’Etoile, France). Cultures repeatedly yielded A fumigatus. The dialysis catheter was removed and cultured on Sabouraud dextrose agar containing chloramphenicol; A fumigatus grew after two days of incubation. The galactomannan antigen detection test (Platelia® Aspergillus; Bio-Rad, Marnes-La-Coquette, France) performed once on the patient’s serum revealed a positive value of 3.5 (normal value, < 0.8; doubtful, 0.8–1.0; positive, > 1.0). Oral voriconazole 400 mg twice daily was started promptly because peritoneal aspergillosis was considered very likely. Unfortunately, the patient died after 24 hours of antifungal treatment.

Peritonitis caused by fungi of the Aspergillus spp is rare in patients with continuous ambulatory peritoneal dialysis and is associated with high mortality.2–5 Early detection, peritoneal catheter removal, and appropriate treatment with antifungal drugs may improve outcome.2–5 However, it is not clear whether voriconazole is the treatment of choice, because it has never been used in this setting, and there are no data available on voriconazole concentration in peritoneal fluid.

Galactomannan detection in serum and maybe also in peritoneal fluid, in addition to the polymerase chain reaction (if available), may contribute to an early diagnosis.

References

  • 1.Scotter JM, Stevens JM, Chambers ST, et al. Diagnosis of Aspergillus peritonitis in a renal dialysis patient by PCR and galactomannan detection. J Clin Pathol 2004;57:662–4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Miles AM, Barth RH. Aspergillus peritonitis: therapy, survival, and return to peritoneal dialysis. Am J Kidney Dis 1995;26:80–3. [DOI] [PubMed] [Google Scholar]
  • 3.Tanis BC, Verburgh CA, van ‘t Wout JW, et al. Aspergillus peritonitis in peritoneal dialysis: case report and review of the literature. Nephrol Dial Transplant 1995;10:1124–5. [PubMed] [Google Scholar]
  • 4.Nannini EC, Paphitou NI, Ostrocky-Zeichner L. Peritonitis due to Aspergillus and zygomycetes in patients undergoing peritoneal dialysis: report of 2 cases and review of the literature. Diagn Microbiol Infect Dis 2003;46:49–54. [DOI] [PubMed] [Google Scholar]
  • 5.Bren A . Fungal peritonitis in patients on continuous ambulatory peritoneal dialysis. Eur J Clin Microbiol Infect Dis 1998;17:839–43. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES